⌕
Pulse Biosciences · PLSE · Nasdaq
Tenet 46 · Mixed
Compare
$44.84−3.28%At closeTenet 46 · Mixed
$44.84−1.52 (−3.28%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Pulse Biosciences (PLSE) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

34 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 75% below its peak, net margin −20794.6%. Worth your attention in FY25: Share count (+143.1%) and Capex step-up ($315.0K). Both visible in the receipts below.
The lines that matter · FY21–FY25
Revenue ($K)—
350.0
FY21→FY25CAGR −29.5%/yr
Net income ($K)▼35.8%
−72,781.0
FY21→FY25CAGR —
Free cash flow ($K)▼49.3%
−54,437.0
capex stepped upCAGR —
What the receipts whisper · what a headline number hides
Share count
+143.1%

28.0mn → 68.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$315.0K

▲152% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

Returns vs FCF
n/m

$0.0M returned vs $−54.4M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)350.0Revenue−539.0COGS−189.0Gross profit−44721.0R&D−32029.0SG&A−76939.0Op income4158.0Tax & other−72781.0Net income

-20795¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
108530%sector median net margin ~3%FY21FY25

Over this window: gross -38.8% → -54.0%. Net margin -20794.6% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
1,494.0350.00.00.0700.01,418.0—−29.5%
Cost of revenue
1,094.0539.00.00.011,944.01,968.0—−27.7%
Gross profit
400.0−189.0—A—A−11,244.0−550.0——
Research & development
57,341.044,721.032,336.027,797.020,839.028,640.0▲38.3%+11.8%
Selling, general & admin
30,026.032,029.023,921.015,777.013,955.019,073.0▲33.9%+13.8%
Total operating expenses
87,367.076,750.056,257.043,574.046,813.062,464.0▲36.4%+5.3%
Operating incomefeeds ROC rank
−86,967.0−76,939.0−56,257.0−43,574.0−58,057.0−63,014.0▼36.8%—
Other income, net
3,245.04,158.02,672.01,364.0−448.0−646.0——
Pretax income
−83,722.0−72,781.0−53,585.0−42,210.0−58,505.0−63,660.0▼35.8%—
Income tax
———0.00.00.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−83,722.0−72,781.0−53,585.0−42,210.0−58,505.0−63,660.0▼35.8%—
Per share
Diluted shares (mn)
73.5567.9967.2755.2337.5927.96▲1.1%+24.9%
Margins
Gross margin
26.8%−54.0%—A—A−1606.3%−38.8%——
Operating margin
−5821.1%−21982.6%——−8293.9%−4443.9%——
Net margin
−5603.9%−20794.6%——−8357.9%−4489.4%——
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY15 – FY20 · 6 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 6 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-19 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Pulse Biosciences' net income?

Pulse Biosciences reported net income of −$72,781.0K in fiscal 2025, a net margin of −20794.6%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.